New Drug Applications

US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia

8 years ago
by David Miller
957 Views
Written by David Miller

April 3, 2018 AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts
[mwai_chat window="true" fullscreen="true"]